Piperacetazine versus thioridazine in the treatment of organic brain disease: a controlled double-blind study.
In a double-blind cross-over study, 50 geriatric patients with organic brain disease were divided into two groups. One group first received piperacetazine for 15 days and then thioridazine for 15 days. For the other group the sequence was reversed. Piperacetazine proved to be at least as effective as thioridazine and seemed to be more effective against certain target symptoms; side effects were less common and less severe.
D000368:Aged; D014150:Antipsychotic Agents / Q000627:therapeutic use*; D001007:Anxiety / Q000188:drug therapy; D001927:Brain Diseases / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010640:Phenothiazines / Q000009:adverse effects / Q000627:therapeutic use*; D011569:Psychiatric Status Rating Scales; D013881:Thioridazine / Q000009:adverse effects / Q000627:therapeutic use*; D013997:Time Factors
D014150:Antipsychotic Agents; D010640:Phenothiazines; D013881:Thioridazine